Evidence map›Paper›PMID 42243460›Full record

Trial reportJournal of pharmacokinetics and pharmacodynamics2026

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Yibo Wang, Mark Hadigol, Victor Ruberio Lincha, Justin Hoffman, Arun A Azad, Neeraj Agarwal, Nobuaki Matsubara, Fabian Zohren, Liza DeAnnuntis, Diane D Wang

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03395197 (A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03395197 phase3active not recruitingnot on this map

A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer

TypeinterventionalSponsorPfizerRan2017 to 2027Enrolled1,054ConditionsmCRPCArmsTalazoparib with enzalutamide, Placebo with enzalutamide
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yibo WangPfizer Inc, La Jolla, CA, USA. ywang797@its.jnj.com.
Mark HadigolPfizer Inc, La Jolla, CA, USA.
Victor Ruberio LinchaPfizer Inc, La Jolla, CA, USA.
Justin HoffmanPfizer Inc, La Jolla, CA, USA.
Arun A AzadPeter MacCallum Cancer Centre, Melbourne, Australia.
Neeraj AgarwalHuntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, USA.
Nobuaki MatsubaraNational Cancer Center Hospital East, Chiba, Japan.
Fabian ZohrenPfizer Inc, La Jolla, CA, USA.
Liza DeAnnuntisPfizer Inc, La Jolla, CA, USA.
Diane D WangPfizer Inc, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TALAPRO-2 trial (NCT03395197) showed that the addition of talazoparib, a potent PARP inhibitor, to enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC. Due to adverse events (AEs), approximately 62% of patients experienced dose interruption and 53% of patients experienced dose reduction of talazoparib in TALAPRO-2 trial. Hematologic AEs such as anemia, thrombocytopenia, and neutropenia were the most common AEs leading to dose interruptions or reductions. We investigated the relationship between talazoparib exposure as well as baseline patients/disease characteristics and Grade ≥ 3 anemia, thrombocytopenia, and neutropenia using graphical examination and Cox proportional hazard models. The results indicated that higher talazoparib exposure, C

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzamidesNitrilesPhenylthiohydantoinPhthalazinesProstatic Neoplasms, Castration-ResistantAgedAnemiaDose-Response Relationship, DrugHumansMaleMiddle AgedNeutropeniaPoly(ADP-ribose) Polymerase InhibitorsProgression-Free SurvivalThrombocytopeniaBenzamidesenzalutamideNitrilesPhenylthiohydantoinPhthalazinesPoly(ADP-ribose) Polymerase InhibitorstalazoparibExposure metricsExposure-responsemCRPCTalazoparibTime-varying exposure

Identifiers

PMID42243460
PMCPMC13236835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.